<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651882</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-Nr: 2017-01750</org_study_id>
    <nct_id>NCT03651882</nct_id>
  </id_info>
  <brief_title>Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections</brief_title>
  <official_title>Intramyometrial and Intravenous Oxytocin Compared to Intravenous Carbetocin for Prevention of Postpartum Hemorrhage in Elective Cesarean Sections - a Monocentric Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective is to proof non-inferiority of intramyometrial and intravenous oxytocin application
      compared to intravenous carbetocin for prevention of postpartum hemorrhage in planned,
      uncomplicated cesarean deliveries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Before c-section the patients will be randomized to the oxytocin or the carbetocin group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of women with a delta hemoglobin ≥ 30g/l.</measure>
    <time_frame>48 hours</time_frame>
    <description>Delta hemoglobin is defined as the difference of the hemoglobin at admission minus the hemoglobin after delivery, usually 24-48 hours after the delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>decrease in hemoglobin (delta hemoglobin, in g/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>estimated blood loss (in mL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>incidence of PPH (in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>use of additional uterotonic agents (prostaglandines)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>blood transfusion (number of packed red cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15-300 minutes</time_frame>
    <description>length of surgery (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>number of patients with revision (second surgery in the 24hours following the primary cesarean section)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome parameters</measure>
    <time_frame>15 days</time_frame>
    <description>admission to an intensive care unit (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Carbetocin is given 0.1mg intravenously as a bolus after delivery.</description>
    <arm_group_label>Carbetocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective cesarean section

          -  present informed consent

          -  completed 36 weeks of gestation

        Exclusion Criteria:

          -  need for intubation (carbetocin is only licensed for epidural or spinal anesthesia)

          -  multiple fetus pregnancy

          -  known coagulopathy

          -  Placenta praevia

          -  morbidly adherent placenta

          -  placental abruption

          -  thrombocyte dysfunction

          -  HELLP-syndrome

          -  preeclampsia

          -  history of uterine atony
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Haslinger, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Haslinger, M.D.</last_name>
    <phone>+41 44 255 4613</phone>
    <email>Christian.Haslinger@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Haslinger, MD</last_name>
      <email>christian.haslinger@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

